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In rheumatology and other medical specialties there is a discrepancy between the widespread use and
the imprecise designation of glucocorticoid treatment regimens. Verbal descriptions of glucocorticoid
treatment regimens used in various phases of diseases vary between countries and institutions. Given
this background, a workshop under the auspices of the EULAR Standing Committee on International
Clinical Studies including Therapeutic Trials was held to discuss this issue and to seek a consensus on
nomenclature for glucocorticoid treatment. This report summarises the panel’s discussion and
recognises that answers derived from consensus conferences are not definitive. Nevertheless,
recommendations on glucocorticoid treatment are presented that (1) reflect current and best knowledge
available and (2) take into account current clinical practice. A question-answer rationale presentation
style has been chosen to convey the messages, to summarise the meeting in a readable format, and to
avoid dogmatism.
Glucocorticoids have profound anti-inflammatory andimmunosuppressive actions when used therapeuti-cally. The therapeutic dose is very wide and depends on
the indication for treatment, but can vary more than 200-fold.
Clearly, different dosages and dosing regimens have distinct
therapeutically relevant effects mediated by genomic and
non-genomic actions. Genomic actions involve the binding to
cytosolic glucocorticoid receptors, occur at any therapeutically
relevant dosage, and are seen not earlier than 30 minutes after
receptor binding. In contrast, non-genomic actions are medi-
ated via biological membranes, and are seen at higher concen-
trations and within seconds or minutes (see below). However,
the basis for the use of different dosages in different clinical
conditions is essentially empirical as the evidence to support
preferences in specific clinical settings is very scarce. This is
aggravated by the discrepancy between the widespread use
and the imprecise designation of glucocorticoid treatment
regimens in rheumatology, as in other medical specialties.
Nomenclature and terminology of glucocorticoid treatment
regimens used in various indications and phases of diseases
varies between countries and institutions. The current termi-
nological confusion is exemplified by the different interpreta-
tions of the various terms used to describe dosage (very low,
low, mild, mild to moderate, moderate, high, very high, ultra-
high, and megadoses) and by the great variation in interpret-
ation of the terms “low dose therapy”, “high dose therapy”,
and “pulse therapy”. A clarification of this situation is needed,
firstly, for scientific conciseness in clinical terms to compare
trials and, secondly, because glucocorticoid actions are
strongly dose dependent in both a quantitative and qualitative
manner.1 2 Moreover, it should be noted that there is currently
a renewed interest in glucocorticoids based on studies
describing their disease modifying effects in rheumatoid
arthritis.3–5
Given this background, a workshop was held to discuss this
issue and to seek a consensus on nomenclature for glucocorti-
coid treatment. A panel of experts was convened under the
auspices of the EULAR Standing Committee on International
Clinical Studies including Therapeutic Trials. The panel
comprised rheumatologists from Germany, the United King-
dom, Italy, Portugal, Switzerland and The Netherlands who
met in Berlin on 7 April 2001 for the First EuropeanWorkshop
on Glucocorticoid Therapy. This report summarises the panel’s
discussion and recognises that answers derived from consen-
sus conferences are not definitive. Nevertheless, we present
recommendations on glucocorticoid treatment that (1) reflect
current and best knowledge available and (2) take into
account current clinical practice. We have chosen a question-
answer rationale presentation style to convey the messages, to
summarise our meeting in a readable format, and to avoid
dogmatism.
WHAT TERM SHOULD BE USED TO DESCRIBE THIS




We suggest the use of the term glucocorticoids.
Rationale
The term steroids is too broad as it simply describes chemical
compounds characterised by a common multiple ring struc-
ture that include molecules such as cholesterol, sex hor-
mones, and corticosteroids. The terms corticosteroids and
corticoids are insufficiently exact as the adrenal cortex syn-
thesises two classes of steroids: the corticosteroids in the
narrower sense, which have 21 carbon atoms, and androgens,
which have 19 carbon atoms. The adrenal corticosteroids in
the narrower sense differ in their relative glucocorticoid (car-
bohydrate metabolism regulating) and mineralocorticoid
(electrolyte balance regulating) activity and were, therefore,
historically described as glucocorticoids and
mineralocorticoids.6 Corticosteroids are grouped according to
their relative potencies in Na+ retention, effects on carbohy-
drate metabolism (hepatic deposition of glycogen and
glucogenesis), and anti-inflammatory effects.6 Potencies based
on effects on glucose metabolism (but not effects on Na+
retention!) closely parallel those for anti-inflammatory effects.
This was the reason for using the term glucocorticoids where
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anti-inflammation is the therapeutically desired effect. In
humans, hydrocortisone (cortisol) is the main glucocorticoid,
and aldosterone is the main mineralocorticoid.6 Glucocorti-
coids in therapeutic use for anti-inflammatory and immuno-
suppressive effects are nowadays exclusively synthetic mol-
ecules that have pronounced anti-inflammatory potencies
compared to relative weak or even zero Na+ retaining
potencies.
For these reasons the terms glucocorticoid(s) or gluco-
corticosteroid(s) are scientifically correct and appropriate to
describe the use of these drugs for the treatment of rheumatic
diseases and other conditions where anti-inflammatory and
immunomodulatory effects are desired. However, the term
“glucocorticosteroids” is not very often used (only 368
citations in Medline 1994–2000) compared to the term
“glucocorticoids” (11 178 citations). In summary, we suggest
generally the use of the term glucocorticoid(s).
HOW CAN GLUCOCORTICOID THERAPY
SCHEDULES BE DESCRIBED AS PRECISELY AS
POSSIBLE?
Answer
We suggest a description that is precise regarding (a) the drug,
(b) the dosage, (c) the route of administration, and (d) the
timing of administration (timing, frequency, duration, some-
times cumulative dosage where appropriate).
Rationale
(a) Drug
It is absolutely necessary to provide the full name of the drug,
as different glucocorticoid drugs have different drug poten-
cies. Moreover, glucocorticoids produce distinct therapeuti-
cally relevant effects. Genomic effects are mediated by
cytosolic receptors that alter expression of specific genes. Spe-
cific non-genomic effects occur within a few minutes and are
mediated by steroid selective membrane receptors. Non-
specific non-genomic effects occur within seconds, but only at
high glucocorticoid dosages, and seem to result from direct
interactions with biological membranes. It should be noted
that clinical importance and therapeutic relevance of these
rapid glucocorticoid effects remain unclear at present,
although current basic research results on their existence are
very convincing. More detailed information on these matters
are available in a recent review.7
Drug potencies are usually described by the equivalent dos-
ages as given in figure 1. The left part of the figure shows the
well known relative potencies of important glucocorticoids to
produce classic genomic effects. These values have been in use
for decades although experimental and clinical evidence for
their preciseness is weak. Nevertheless, these relations are
usable for daily clinical work in terms of general therapeu-
tic guidelines, but their dogmatic use should be avoided. We
suggest therefore that (1) these values continue to be used
until more exact data are available and (2) doses of different
glucocorticoids are expressed by converting them into doses of
“prednisone equivalent”; in other words to express doses of
different glucocorticoids in mg prednisone (=mg pred-
nisolone, as prednisone is equally as potent as prednisolone)
by using the relative potencies given above. The suggestion for
further using the term prednisone equivalent is recommended
for historical reasons because prednisone was the first
synthetic, pharmacologically relevant glucocorticoid drug to
be introduced into clinical medicine.
However, (1) It should be noted that the use of equivalent
dosages is according to recent data only a valid procedure if
doses of less than 100 mg prednisone are considered. At
higher doses non-genomic effects come into play. This is
important because the relative potencies of different glucocor-
ticoids producing these non-genomic effects are completely
different from their classic genomic effects.2 8 9 Figure 1B
shows the data that rationalise the empirical use of glucocor-
ticoids for high dose therapy. For instance, for pulse therapy
methylprednisolone is often preferred to prednisolone in
exacerbated immunologically mediated disorders. The two
drugs have similar genomic potency but in high dose therapy
the non-specific non-genomic effect of methylprednisolone is
more than threefold stronger. This may explain the empirical
clinical preference for methylprednisolone. Another example
is the very low non-genomic potency of betamethasone,which
may be one reason why this drug is rarely used systemically
although it has the same genomic potency as dexamethasone.
In summary, the clinical use of different glucocorticoids is
clearly determined by their magnitude of clinical efficacy, but
one underlying reason for this may be their non-genomic
potencies.
(2) For an individual patient the dose of the specific drug
should be given instead of calculating the prednisone equival-
ent.
(b) Dosage
The dose defines the strength of effects and side effects. This
relates to glucocorticoid receptor saturation (the more
receptors are occupied the more effect is exerted) and very
likely to the occurrence of additional non-genomic effects at
higher doses (fig 2).
(c) Route of administration
An absolutely necessary specification to be given for
describing glucocorticoid therapy is whether the drug is
administered orally, intravenously, intramuscularly, or intra-
articularly. In this regard we consider intra-articular applica-
tion as a special form of (local) high dose therapy where local
Figure 1 Relative potencies of
various glucocorticoids to produce
genomic and non-specific
non-genomic effects. The figure shows
a comparison between genomic and
non-genomic potencies of various
glucocorticoids. (A) Data for classic
(genomic) effects were taken from
Goodman and Gilman6 and are rela-
tive to cortisol. (B) Data for non-
specific non-genomic effects were
taken from Schmid et al8 and are rela-
tive to prednisolone. The value for
prednisolone was set to 4 and values
for the other glucocorticoids were
scaled accordingly to allow direct
comparison with the classic poten-
cies. It should be noted that non-
specific non-genomic effects are
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concentrations are reached that can, in addition to the most
important genomic effects, also exert non-genomic effects. It
should be noted that the range of glucocorticoids available for
intra-articular administration is larger than the range for sys-
temic use. Moreover, these intra-articular glucocorticoids dif-
fer significantly in structure with important consequences on
their therapeutic effects.
(d) Time
We consider the following criteria to be of relevance for gluco-
corticoid effects and side effects:
Timing
At what hour of the day is the glucocorticoid drug given? This
question is of special importance against the background of
(1) circadian rhythm of endogenous cortisol production,
which may be changed in some rheumatic conditions, and (2)
also in view of the diurnal variation of symptoms, particularly
morning stiffness in inflammatory polyarthritis. Although
research in this area of chronobiology is still limited, several
findings suggest that our current paradigms about timing of
glucocorticoid administration need to be questioned by
appropriate investigation, both in terms of efficacy and safety.
Frequency
How often is the glucocorticoid drug given each day—once a
day or is there a dose splitting?
Duration
What is the duration of a defined treatment schedule given in
days, weeks, months, or even years?
Note that (1) each period of glucocorticoid treatment
(“treatment schedule”) should be described in these terms,
and (2) “tapering” the dose is a frequent procedure either to
approach the maintenance dose or to stop the glucocorticoid
therapy.
Cumulative dose
Many adverse effects of glucocorticoid treatment (such as
glucose intolerance and osteoporosis) are related to cumula-
tive tissue exposure. We therefore suggest describing the
cumulative dose, especially in long term therapy. Currently the
calculation of cumulative doses is used rather for scientific
reasons.
In summary, we suggest that an appropriate description of
a given glucocorticoid therapy regimen should follow this
example:
Initially x mg prednisone orally once a day (at 8 00 am) for
two weeks, then reduced to y mg prednisone a day, followed
by . . .(describe each step of reduction in terms of mg and
time) reaching zero after for example, one year (overall dura-
tion). The cumulative dose was z mg prednisone.
WHAT SHOULD BE THE DEFINITION OF
CONVENTIONAL TERMS FOR GLUCOCORTICOID
DOSES?
Answer
We suggest the following terminology:
• Low dose <7.5 mg prednisone equivalent a day
• Medium dose >7.5 mg, but <30 mg prednisone equival-
ent a day
• High dose >30 mg, but <100 mg prednisone equivalent
a day
• Very high dose >100 mg prednisone equivalent a day
• Pulse therapy >250 mg prednisone equivalent a day for
one or a few days.
Rationale
As mentioned above glucocorticoids act via genomic and non-
genomic effects.1 2 7 For genomic effects the degree of cytosolic
receptor saturation is considered as a direct modulator of the
intensity of (therapeutic) glucocorticoid effects. Unfortu-
nately, there are no precise data available that describe the
relationship between administered glucocorticoid dose and
consequent occupation of the receptors. Moreover, it has to be
taken into account that there is a wide interindividual
variation in plasma concentrations where the same single
(oral) dose of glucocorticoid is given. However, it has been cal-
culated from known binding constants, free steroid concentra-
tions, and other variables that oral doses of 7.5 mg and 15 mg
of prednisolone would result in blood concentrations eight
hours after the dose that would bind the receptors to 42% and
63% of saturation, respectively,.10 According to this calculation,
higher doses (for example, 100 mg or more) would be required
to result in nearly complete receptor saturation.10 These
considerations led to our proposal above, together with the
fact that clinicians in their daily practice have already created
landmark glucocorticoid doses that are still cloudy in their
definition but clearly group around 7.5, 30, and 100 mg pred-
nisolone equivalent a day.We have used these landmark doses
for defining the terminology suggested above for the following
reasons (see also fig 2):
Low dose
We consider a low dose glucocorticoid treatment as a
treatment with<7.5 mg prednisone equivalent a day, because:
• This dose occupies less than 50% of the receptors
• This dose range is often used for maintenance therapy for
many rheumatic diseases requiring glucocorticoids11 12
• Relatively few adverse effects (such as osteoporosis) are
expected.
Figure 2 Current view on the dose dependency of genomic and
non-genomic effects providing arguments for the description of
glucocorticoid dosages. Figure 2 summarises the current knowledge
on the occurrence of genomic and non-genomic effects in terms of a
dose-response relationship.1 2 6–10 This provided the basis for our rec-
ommendations on how to describe glucocorticoid doses; however,
arguments concerning clinical feasibility have been taken into
account. Against this background we stress that neither for genomic
nor for non-genomic effects is there an exact knowledge of the rela-
tionship between dosage, concentration, and cellular and clinical
effects (see text). However, this figure represents the result of our
interpretation of currently available information on basic research
results and clinical practice.
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The recognition that a relative hypocortisolism is present in
chronic inflammatory conditions (for example, rheumatoid
arthritis, polymyalgia rheumatica)13 leads some observers to
regard low dose glucocorticoid treatment as a means of
replacement therapy for the reduced adrenal production.14
Medium dose
We consider an administered dose of >7.5 mg, but <30 mg
prednisone equivalent a day to be a medium dose, because
• These doses lead to a significantly higher receptor
engagement ranging above 50% but below 100%
• Doses between 7.5 mg and 30 mg are effective if given
initially in various conditions of rheumatic diseases (pri-
mary chronic rheumatic diseases)
• It is a “natural barrier” in the sense that most
rheumatologists do not initially treat most patients (for
example, those with non-complicated rheumatoid arthri-
tis or polymyalgia rheumatica) with doses above 30 mg15
• Side effects are considerable and dose dependent in this
range if treatment is given for longer periods
High dose
We consider doses between >30 mg and<100 mg prednisone
equivalent a day to be high doses, because:
• These doses significantly increase receptor saturation in a
dose dependent manner resulting in an almost complete
receptor saturation at approximately 100 mg/day where
up to 100% of genomic glucocorticoid effects are assumed
to be exerted10
• High doses as defined above are usually and successfully
given as initial treatments for subacute rheumatic
diseases such as non-life threatening exacerbations or
visceral complications of rheumatoid arthritis or other
connective tissue diseases16 17
• These doses cannot be administered for long term
therapy because of the occurrence of severe side effects
Very high dose
We consider doses >100 mg prednisone equivalent a day to be
very high doses, because:
• Above 100 mg prednisone equivalent a day there is virtu-
ally a 100% receptor saturation with regard to cytosolic
receptors. Therefore, a further increase in dose may affect
the pharmacodynamics (for example, receptor off load-
ing and re-occupancy), receptor synthesis, and expres-
sion, but may also bring additional therapeutic benefit
via other mechanisms. This assumed additional thera-
peutic benefit of very high doses could be obtained via
qualitatively different, non-genomic effects. These effects
are either mediated by membrane bound receptors or are
initiated by physicochemical interactions with cellular
membranes.1 2 7 It is not yet clear if these effects are
directly of therapeutic relevance, but experimental data
suggest that these differential effects come increasingly
into play above around 100 mg/day (figs 1 and 2)
• These doses are often successfully given as initial doses
for acute or life threatening exacerbations of rheumatic
diseases such as connective tissue diseases, vasculitis,
and rheumatoid arthritis.17–19
• These doses cannot be given for long term treatment
because of the occurrence of dramatic side effects.
Pulse therapy
We consider “pulse therapy” as a specific therapeutic entity
that refers to the administration of >250 mg prednisone
equivalent a day (usually intravenously) for one or a few
(usually <5) days. It should be stressed that this term rather
refers to the very high dose given than to its intermittent
character in terms of time. We have the following arguments
to support this suggestion. The first is that in common clinical
practice doses of 250 mg/day or above are usually only used in
terms of pulse therapy. Thus these doses are exclusively given
for a few days, but then reduced or stopped directly. The sec-
ond argument is that at these doses non-genomic potencies of
glucocorticoids come into play. It is likely that these are the
reasons for the clinical finding that generally very high
dosages and pulse therapy are successful in acute exacerba-
tions of immunologically mediated diseases. The immediate
effects produced by very high dosages could be additive to the
genomic effects mediated by cytosolic glucocorticoid recep-
tors. The additional quantum of inhibition of the excessive
immune processes could make a crucial contribution to the
therapeutic effect by helping to terminate the acute exacerba-
tion. In rheumatology and clinical immunology, acute
episodes or particularly severe forms of rheumatic diseases
such as systemic lupus erythematosus, vasculitis, polymyosi-
tis, and rheumatoid arthritis are examples of the circum-
stances where very high doses or pulse glucocorticoid therapy
can be successful.17–19 Pulse therapy results in termination of
the exacerbation or regression of severe forms of disease in a
high proportion of cases with a relatively low incidence of side
effects. Non-genomic mechanisms of glucocorticoid action
may also provide an explanation for the beneficial therapeutic
effect of pulse glucocorticoid therapy for many other
indications. These include the treatment of acute spinal inju-
ries and use in immune thrombocytopenia, juvenile dermato-
myositis, juvenile chronic arthritis, optic neuritis, rapid
progressive glomerulonephritis, and pemphigus vulgaris.
Non-genomic mechanisms offer a possible explanation for
benefits, such as very early clinical response, which cannot be
extrapolated from the dose-response effects of medium or low
dose therapy.
CONCLUSION
These proposals for nomenclature of glucocorticoid treatment
are made in the hope that scientific consensus and clarity can
be improved and that the nomenclature relates in some way to
mechanisms of action. We stress that our proposals are tenta-
tive, but are consistent with current knowledge. Although
glucocorticoids have immense therapeutic benefits and are
widely used, many issues remain to be clarified. These include
their detailed mechanisms of action, and the rationale for the
use of various doses/regimens or measures to reduce adverse
effects. Accordingly, much effort will need to be invested to
obtain greater insight, and this will then guide any future
revision of the nomenclature.
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Keeping up appearances
Biopsy of the temporal artery can be used to confirm giant cell arteritis (GCA) well after corticosteroidtreatment has started, according to a small prospective study. The findings will need to be verified bya larger study, but it now seems that treatment need not be delayed for a biopsy for fear of compro-
mising the histological picture. Usually, a biopsy is performed within two weeks of starting treatment.
Temporal artery biopsy specimens from nine of the 11 patients in the study showed features of GCA—
that is, giant cells in the intima and media, lymphocytes and histiocytes in the media, reduplication or
fragmentation of the internal elastic lamina, and thickening of the intima. In two of the nine the appear-
ance indicated healed GCA. Three of four specimens (75%) were positive within two weeks after starting
corticosteroid treatment and six of seven (86%) after 4–6 weeks.
The patients received a standardised regimen of high dose corticosteroids according to whether they
had visual loss on referral or not. At entry to the study they were randomised to receive biopsy before
treatment; within in week after treatment started; at 2–3 weeks; and at 4–6 weeks. Patients were receiv-
ing at least 40 mg prednisolone when undergoing biopsy. Each paraffin block of biopsy material was cut
at 4–5 µm thickness in at least three levels for staining and histological examination.
Previously there has been controversy about whether corticosteroid treatment obscures the pathologi-
cal features of biopsy material, but this has been based on retrospective studies.
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